Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Aronex reports responses in phase II trial of Atragen as treatment of NHL

June 30, 1999

New compounds from Merck inhibit posttranslational farnesylation of proteins

June 30, 1999

FeRx's targeted carrier tested in doxorubicin delivery to liver cancer patients

June 30, 1999

QLT terminates collaboration with Beaufour Ipsen

June 30, 1999

Continued focus at Merck on inhibitors of protein farnesyltransferase

June 29, 1999

Ligand submits NDA for Targretin capsules and reports positive interim data from psoriasis study

June 29, 1999

Magainin begins phase II testing of squalamine

June 29, 1999

Ethyol approved by FDA for radiation-induced dry mouth

June 28, 1999

Et-743, a potent anticancer agent with a complex, unique mechanism of action

June 28, 1999

BioInvent will supply Theragyn for Antisoma

June 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...